At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

Two of Gilead Sciences' most important drugs, Biktarvy and Trodelvy, missed Wall Street's sales expectations, and Gilead stock slumped Friday. Biktarvy, an HIV treatment, is Gilead's biggest ...

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...

The dispute centred around Gilead's triple-drug regimen Biktarvy, which is based on emtricitabine, tenofovir alafenamide and integrase inhibitor bictegravir. ViiV claimed the latter compound ...

Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some ...

Gilead, in its release last week of the company's first quarter operating results of 2025, noted that Biktarvy sales increased 7% to $3.1 billion for the quarter, compared to the first quarter of ...

Adjusted profit $1.81 per share vs analyst estimates of $1.79 Company says FDA lenacapavir review still expected by June 19 Biktarvy sales rise 7%, cell therapy sales fall 3% April 24 (Reuters) - ...